depression cannabidiol - PMC

James Hotham, Rebecca Cannings-John, Laurence Moore, Jemma Hawkins, Chris Bonell, Matthew Hickman, Stanley Zammit, Lindsey A. Hines, Linda Adara, Julia Townson, James White

Br J Psychiatry. 2023 Oct; 223(4): 478–484. doi: 10.1192/bjp.2023.91

PMCID:: PMC10866672

Article PDF–303K

Select item 73854254.

Cannabidiol as a Treatment for Mood Disorders: A Systematic Review: Le cannabidiol comme traitement des troubles de l’humeur: une revue systématique

Jairo Vinícius Pinto, Gayatri Saraf, Christian Frysch, Daniel Vigo, Kamyar Keramatian, Trisha Chakrabarty, Raymond W. Lam, Márcia Kauer-Sant’Anna, Lakshmi N. Yatham

Can J Psychiatry. 2020 Apr; 65(4): 213–227. doi: 10.1177/0706743719895195

PMCID:: PMC7385425

Article PDF–410K

Select item 101901505.

The NLRP3 Inflammasome in Stress Response: Another Target for the Promiscuous Cannabidiol

Alice Hartmann, Carla Vila-Verde, Francisco S. Guimarães, Sâmia R. Joca, Sabrina F. Lisboa

Curr Neuropharmacol. 2023 Feb 1; 21(2): 284–308. Published online 2023 Feb 1. doi: 10.2174/1570159X20666220411101217

PMCID:: PMC10190150

Article PDF–4.0M

Select item 109245816.

Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude pilote

Jairo Vinícius Pinto, José Alexandre S. Crippa, Keila Maria Ceresér, Miréia Fortes Vianna-Sulzbach, Érico de Moura Silveira Júnior, Gabriel Santana da Rosa, Manoella Guatimuzim Testa da Silva, Gabriel Henrique Hizo, Leonardo Simão Medeiros, Carlos Eduardo Santana de Oliveira, Giovana Bristot, Alline Cristina Campos, Francisco Silveira Guimarães, Jaime E. C. Hallak, Antonio W. Zuardi, Lakshmi N. Yatham, Flávio Kapczinski, Márcia Kauer-Sant’Anna

Can J Psychiatry. 2024 Apr; 69(4): 242–251. Published online 2023 Nov 3. doi: 10.1177/07067437231209650

PMCID:: PMC10924581

Article PDF–927K

Select item 118205647.

Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims

Barbara E. Engeli, Dirk W. Lachenmeier, Patrick Diel, Sabine Guth, Maria A. Villar Fernandez, Angelika Roth, Alfonso Lampen, Alexander T. Cartus, Wim Wätjen, Jan G. Hengstler, Angela Mally

Nutrients. 2025 Feb; 17(3): 489. Published online 2025 Jan 29. doi: 10.3390/nu17030489

PMCID:: PMC11820564

Article PDF–1.4M

Select item 117635968.

Cannabidiol Modulates Neuroinflammatory and Estrogen-Related Pathways in a Sex-Specific Manner in a Chronic Stress Model of Depression

Uri Bright, Irit Akirav

Cells. 2025 Jan; 14(2): 99. Published online 2025 Jan 10. doi: 10.3390/cells14020099

PMCID:: PMC11763596

Article PDF–1.8M

Select item 99588689.

Cannabinoid Receptor 2 Blockade Prevents Anti-Depressive-like Effect of Cannabidiol Acid Methyl Ester in Female WKY Rats

Danielle Hen-Shoval, Lital Moshe, Talia Indig-Naimer, Raphael Mechoulam, Gal Shoval, Gil Zalsman, Natalya M. Kogan, Aron Weller

Int J Mol Sci. 2023 Feb; 24(4): 3828. Published online 2023 Feb 14. doi: 10.3390/ijms24043828

PMCID:: PMC9958868

Article PDF–2.7M

Select item 825445410.

Cannabidiol prevents lipopolysaccharide-induced sickness behavior and alters cytokine and neurotrophic factor levels in the brain

Pedro Augusto Lopes Tito, Túlio Cézar de Souza Bernardino, Paula Maria Quaglio Bellozi, Maria Carolina Machado da Silva, Aline Silva de Miranda, Érica Leandro Marciano Vieira, Fabrício A. Moreira, András Palotás, Antônio Carlos Pinheiro de Oliveira, Helton José Reis

Pharmacol Rep. 2021; 73(6): 1680–1693. Published online 2021 Jul 3. doi: 10.1007/s43440-021-00301-8

PMCID:: PMC8254454

Article PDF–2.6M

Select item 1105575611.

Entry of cannabidiol into the fetal, postnatal and adult rat brain

Georgia Fitzpatrick, Yifan Huang, Fiona Qiu, Mark D. Habgood, Robert L. Medcalf, Heidi Ho, Katarzyna M. Dziegielewska, Norman R. Saunders

Cell Tissue Res. 2024; 396(2): 177–195. Published online 2024 Feb 17. doi: 10.1007/s00441-024-03867-w

PMCID:: PMC11055756

Article PDF–2.3M

Select item 879952312.

A Scoping Review of the Use of Cannabidiol in Psychiatric Disorders

Anna E. Kirkland, Matthew C. Fadus, Staci A. Gruber, Kevin M. Gray, Timothy E. Wilens, Lindsay M. Squeglia

Psychiatry Res. Author manuscript; available in PMC 2023 Feb 1.

Published in final edited form as: Psychiatry Res. 2022 Feb; 308: 114347. Published online 2021 Dec 20. doi: 10.1016/j.psychres.2021.114347

PMCID:: PMC8799523

Article PDF–380K

Select item 1009675213.

The Polypharmacological Effects of Cannabidiol

Jorge Castillo-Arellano, Ana Canseco-Alba, Stephen J. Cutler, Francisco León

Molecules. 2023 Apr; 28(7): 3271. Published online 2023 Apr 6. doi: 10.3390/molecules28073271

PMCID:: PMC10096752

Article PDF–2.4M

Select item 616164414.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age

José A. Crippa, Francisco S. Guimarães, Alline C. Campos, Antonio W. Zuardi

Front Immunol. 2018; 9: 2009. Published online 2018 Sep 21. doi: 10.3389/fimmu.2018.02009

PMCID:: PMC6161644

Article PDF–1.1M

Select item 915724415.

Cannabidiol and substance use disorder: dream or reality

Saeideh Karimi-Haghighi, Yasaman Razavi, Daniela Iezzi, Andrew F. Scheyer, Olivier Manzoni, Abbas Haghparast

Neuropharmacology. Author manuscript; available in PMC 2023 Apr 1.

Published in final edited form as: Neuropharmacology. 2022 Apr 1; 207: 108948. Published online 2022 Jan 13. doi: 10.1016/j.neuropharm.2022.108948

PMCID:: PMC9157244

Article PDF–528K

Select item 971649016.

Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool

Caroline MB Kwee, Joop MA van Gerven, Fleur LP Bongaerts, Danielle C Cath, Gabriël Jacobs, Johanna MP Baas, Lucianne Groenink

J Psychopharmacol. 2022 Dec; 36(12): 1299–1314. Published online 2022 Oct 14. doi: 10.1177/02698811221124792

PMCID:: PMC9716490

Article PDF–1.4M

Select item 1022946717.

Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration

Grace Tsz Yan Yau, Waiting Tai, Jonathon Carl Arnold, Hak-Kim Chan, Philip Chi Lip Kwok

Pharm Res. 2023; 40(5): 1087–1114. Published online 2023 Jan 12. doi: 10.1007/s11095-023-03469-1

PMCID:: PMC10229467

Article PDF–850K

Select item 940931118.

Cannabidiol Prevents Spontaneous Fear Recovery after Extinction and Ameliorates Stress-Induced Extinction Resistance

Eleni P. Papagianni, William G. Warren, Helen J. Cassaday, Carl W. Stevenson

Int J Mol Sci. 2022 Aug; 23(16): 9333. Published online 2022 Aug 19. doi: 10.3390/ijms23169333

PMCID:: PMC9409311

Article PDF–3.1M

Select item 969086819.

Regulation of DNA Methylation by Cannabidiol and Its Implications for Psychiatry: New Insights from In Vivo and In Silico Models

Luana B. Domingos, Nicole R. Silva, Adriano J. M. Chaves Filho, Amanda J. Sales, Anna Starnawska, Sâmia Joca

Genes (Basel) 2022 Nov; 13(11): 2165. Published online 2022 Nov 20. doi: 10.3390/genes13112165

PMCID:: PMC9690868

Article PDF–3.1M

Select item 776546320.

Subacute cannabidiol alters genome‐wide DNA methylation in adult mouse hippocampus

Nicole M Wanner, Mathia Colwell, Chelsea Drown, Christopher Faulk

Environ Mol Mutagen. Author manuscript; available in PMC 2021 Nov 1.

Published in final edited form as: Environ Mol Mutagen. 2020 Nov; 61(9): 890–900. Published online 2020 Aug 10. doi: 10.1002/em.22396

PMCID:: PMC7765463

Article PDF–676K

<< First< Prev

Page of 340

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for depression cannabidiol

Fig. (4)

Plant-derived terpenes against depression (52) Podoandin (53) Cannabidiol (54) Carvacrol (55) β-Caryophyllene (56) Genipin (57) Hyperforin (58) Salvinorin A (59) Ursolic acid.

Depression: An Insight into Heterocyclic and Cyclic Hydrocarbon Compounds Inspired from Natural Sources

Curr Neuropharmacol. 2021 Nov 15;19(11):2020-2037.
Figure 4

Results of the sucrose preference test for rats submitted to a four-week CUMS treatment with or without cannabidiol administration (mean ± SEM, n = 18). (A.) Sucrose preference measured as % preference for sucrose; (B.) sucrose (mL of 1.0% sucrose solution ingested) and water intake on each testing day. CBD, cannabidiol; * p < 0.05 vs baseline.

Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression

Biomolecules. 2020 May;10(5):801.
Figure 3

Results of body weight measurements during a four-week CUMS procedure with or without concomitant cannabidiol (10 mg/kg body weight) treatment. Data are expressed as mean ± 95% confidence interval; * p < 0.05 vs. control.

Effects of Chronic Cannabidiol Treatment in the Rat Chronic Unpredictable Mild Stress Model of Depression

Biomolecules. 2020 May;10(5):801.
Figure 2.

Changes in Montgomery-Åsberg Depression Rating Scale (MADRS) scores. (A) Shows the results of the main analysis. (B) Shows the results of the complementary analysis. *p < 0.05.

Cannabidiol as an Adjunctive Treatment for Acute Bipolar Depression: A Pilot Study: Le cannabidiol comme traitement d'appoint de la dépression bipolaire aiguë : une étude pilote

Can J Psychiatry. 2024 Apr;69(4):242-251.